Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is a biopharmaceutical company dedicated to the development of targeted CNS treatments for diseases such as Alzheimer’s, Parkinson’s, Rett syndrome, and other neurodegenerative and neurodevelopmental disorders. The company focuses on innovative therapeutics, including small molecule treatments targeting the Sigma-1 receptor, with a mission to improve patients' lives through scientific discovery and community engagement.
Industries
Nr. of Employees
small (1-50)
Anavex Life Sciences Corp.
630 5th Avenue, 20th floor, New York, NY 10111 USA
Patents
A2-73 crystalline polymorph compositions of matter and methods of use thereof
US-12180174-B2
View DetailsAnalgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
US-11896590-B2
View Details
A2-73 crystalline polymorph compositions of matter and methods of use thereof
US-12180174-B2
View DetailsAnalgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
US-11896590-B2
View DetailsProducts
Investigational orally available SIGMAR1-activating small molecule (investigational)
An investigational, orally administered small-molecule therapeutic designed to activate an upstream compensatory receptor pathway with the aim of restoring cellular homeostasis and enhancing autophagy in CNS disorders; currently in clinical development.
Investigational orally available SIGMAR1-activating small molecule (investigational)
An investigational, orally administered small-molecule therapeutic designed to activate an upstream compensatory receptor pathway with the aim of restoring cellular homeostasis and enhancing autophagy in CNS disorders; currently in clinical development.
Services
End-to-end clinical program support including protocol design, medical monitoring, study execution, TMF oversight, and coordination with CROs and vendors.
Statistical design and analysis services including SAP development, sample size calculation, programming for derived datasets, and review/validation of tables, figures and listings.
Design and oversight of RWE and pharmacoepidemiology studies to generate evidence from EMR, registries and claims for regulatory, payor, and clinical decision support.
Preclinical and translational experiments to characterize drug mechanism(s), including assays related to autophagy and neuronal homeostasis.
Preparation of regulatory documents, interaction with health authorities, and support for designation requests and risk-management planning.
End-to-end clinical program support including protocol design, medical monitoring, study execution, TMF oversight, and coordination with CROs and vendors.
Statistical design and analysis services including SAP development, sample size calculation, programming for derived datasets, and review/validation of tables, figures and listings.
Design and oversight of RWE and pharmacoepidemiology studies to generate evidence from EMR, registries and claims for regulatory, payor, and clinical decision support.
Preclinical and translational experiments to characterize drug mechanism(s), including assays related to autophagy and neuronal homeostasis.
Preparation of regulatory documents, interaction with health authorities, and support for designation requests and risk-management planning.
Expertise Areas
- Clinical trial management
- Biostatistics and statistical programming
- Epidemiology and real-world evidence (RWE)
- Clinical operations and TMF management
Key Technologies
- Orally available small-molecule therapeutics
- Receptor modulation for CNS (SIGMAR1 modulation implied)
- Autophagy modulation assays and models
- Preclinical in vivo models
News & Updates
Company participation in upcoming healthcare conferences to share progress and insights.
Company reports financial results and updates on business activities.
Research on Blarcamesine's potential to improve autophagy in Alzheimer’s disease.
Company participation in upcoming healthcare conferences to share progress and insights.
Company reports financial results and updates on business activities.
Research on Blarcamesine's potential to improve autophagy in Alzheimer’s disease.